NYSE:BHC (Canada)
Business Description
Bausch Health Companies Inc
NAICS : 325412
SIC : 3741
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Compare
Compare
Traded in other countries / regions
BHC.Canada
•
BVF.Germany
•
BHC.Mexico
•
VRX.Switzerland
•
0QYW.UK
•
BHC.USA
Description
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | -0.03 | |||||
| Debt-to-Equity | -31.48 | |||||
| Debt-to-EBITDA | 7.47 | |||||
| Interest Coverage | 1 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 0.07 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.1 | |||||
| 3-Year EBITDA Growth Rate | 73.3 | |||||
| 3-Year EPS without NRI Growth Rate | 40.3 | |||||
| 3-Year FCF Growth Rate | -5.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 0.57 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.12 | |||||
| 9-Day RSI | 49.93 | |||||
| 14-Day RSI | 44.92 | |||||
| 6-1 Month Momentum % | -65.92 | |||||
| 12-1 Month Momentum % | -68.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.08 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.13 | |||||
| Days Inventory | 162.82 | |||||
| Days Sales Outstanding | 73.61 | |||||
| Days Payable | 71.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.48 | |||||
| Operating Margin % | 17.86 | |||||
| Net Margin % | 0.51 | |||||
| ROA % | 0.15 | |||||
| ROIC % | 12.81 | |||||
| ROC (Joel Greenblatt) % | 95.19 | |||||
| ROCE % | 6.27 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 55.63 | |||||
| Forward PE Ratio | 1.8 | |||||
| PE Ratio without NRI | 55.63 | |||||
| Price-to-Owner-Earnings | 3.76 | |||||
| PS Ratio | 0.28 | |||||
| Price-to-Free-Cash-Flow | 6.22 | |||||
| Price-to-Operating-Cash-Flow | 3.67 | |||||
| EV-to-EBIT | 15.82 | |||||
| EV-to-Forward-EBIT | 12.69 | |||||
| EV-to-EBITDA | 8.04 | |||||
| EV-to-Forward-EBITDA | 6.38 | |||||
| EV-to-Revenue | 2.87 | |||||
| EV-to-Forward-Revenue | 2.87 | |||||
| EV-to-FCF | 61.56 | |||||
| Price-to-Projected-FCF | 0.21 | |||||
| Price-to-Median-PS-Value | 0.27 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.6 | |||||
| Earnings Yield (Greenblatt) % | 6.31 | |||||
| Forward Rate of Return (Yacktman) % | 63.14 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:BHC
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8,192 | ||
| EPS (TTM) ($) | 0.12 | ||
| Beta | 1.15 | ||
| Volatility % | 63.92 | ||
| 14-Day RSI | 44.92 | ||
| 14-Day ATR ($) | 0.661986 | ||
| 20-Day SMA ($) | 6.603 | ||
| 12-1 Month Momentum % | -68.43 | ||
| 52-Week Range ($) | 4 - 29.59 | ||
| Shares Outstanding (Mil) | 361.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bausch Health Companies Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||